Navigation Links
Inovio Pharmaceuticals to Host Second Quarter 2014 Financial Results Call on August 11, 2014
Date:8/1/2014

PLYMOUTH MEETING, Pa., Aug. 1, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that it will host a conference call to report its second quarter 2014 financial results on Monday, August 11, 2014 at 9:00 AM ET. CEO Dr. J. Joseph Kim and CFO Peter Kies will discuss second quarter earnings, provide a corporate update, and participate in a live Q&A with analysts. The update will include clinical development plans for VGX-3100, Inovio's immune therapy targeting pre-cancers and cancers associated with HPV.

The audio presentation will be broadcast online at http://www.investorcalendar.com/IC/CEPage.asp?ID=173061. Investors can also access the presentation through the "Webcast" tab on Inovio's home page at www.inovio.com. This is a listen-only event.

A replay of the conference call will be available beginning two hours after the call until Sep. 11, 2014. To access the replay by telephone, dial 877-660-6853 (domestic) or 201-612-7415 (international) and use passcode 13588210. The replay will also be available as a webcast until November 11, 2014 and can be found under the "Webcast" tab on Inovio's website. 

About Inovio Pharmaceuticals, Inc.

Inovio is revolutionizing the fight against cancer and infectious diseases. Our immunotherapies uniquely activate best-in-class immune responses to prevent and treat disease, and have shown clinically significant efficacy with a favorable safety profile. With an expanding portfolio of immune therapies, the company is advancing a growing preclinical and clinical stage product pipeline. Partners and collaborators include Roche, University of Pennsylvania, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, and University of Manitoba. For more information, visit www.inovio.com.

This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, including safety and efficacy for VGX-3100, that pre-clinical studies and clinical trials may not commence or be completed in the time periods anticipated, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, our ability to support our broad pipeline of SynCon® active immune therapy and vaccine products, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company's technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2013, our Form 10-Q for the quarter ended March 31, 2014, and other regulatory filings from time to time. There can be no assurance that any product in Inovio's pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.

CONTACTS:


Investors:

Bernie Hertel, Inovio Pharmaceuticals, 858-410-3101, bhertel@inovio.com

Media:

Jeff Richardson, Inovio Pharmaceuticals, 267-440-4211, jrichardson@inovio.com

 

Logo - http://photos.prnewswire.com/prnh/20131118/LA18202LOGO


'/>"/>
SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial
2. Inovio Pharmaceuticals to Present at Biotech Showcase 2014 Investor Conference
3. CEO Dr. Joseph Kim to Discuss Inovios Innovative Approach to Treating Cervical Cancer in an Expert Panel
4. Inovio Pharmaceuticals Reports 2013 Third Quarter Financial Results
5. Inovio Pharmaceuticals Therapeutic Vaccine for Hepatitis C Enters Phase I Clinical Trial
6. Inovio Pharmaceuticals to Participate in Immunotherapy Panel and Present at the 12th Annual BIO Investor Forum
7. Inovio Pharmaceuticals Targets Transformation of Monoclonal Antibody Therapies
8. Inovio Pharmaceuticals to Present at Investor Conferences and Town Hall Los Angeles
9. Roche and Inovio Pharmaceuticals partner on Inovios prostate cancer and hepatitis B immunotherapy products
10. Inovio Pharmaceuticals to Present at Upcoming Investor Conferences
11. Inovio Pharmaceuticals Malaria DNA Vaccine Demonstrates Robust Immune Responses in Animal Models
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)...  Transportation Insight, a multi-modal lead logistics solutions provider ... firm with expertise serving clients in the food industry. ... was named a 2017 Food Logistics ... only publication exclusively dedicated to covering the movement of ... "Rick has brought to Transportation Insight a wealth of ...
(Date:3/23/2017)... As a result of diagnostic technology ... of allergic diseases, cutting edge developments in targeted ... ways in which pharmaceutical and biotech companies are ... be both a high quality meeting and a ... immunologists, research scholars and doctors. The event will ...
(Date:3/23/2017)... DES MOINES, Iowa , March 23, 2017 /PRNewswire/ ... news and career resource, has partnered with Indiana ... Indiana organizations and educational institutions to ... stage with the first-ever BioIndiana Hotbed map, an artistic ... A framed print was presented to Vice President ...
Breaking Medicine Technology:
(Date:3/23/2017)... New Braunfels, TX (PRWEB) , ... March 23, 2017 , ... ... a new clinic, located at 960 Gruene Road in Building 2. The clinic is ... co-owner Dr. Andrew Bennett, PT, says opening the company’s second New Braunfels location brings ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... 82% of adults are unaware of the ... do not brush their teeth the minimum two times a day that dentists recommend. The ... missing 51 million hours of school and adults missing 164 million hours of work each ...
(Date:3/23/2017)... ... March 23, 2017 , ... The StayWell Company ... NCQA. The accreditation covers StayWell’s asthma, coronary artery disease, congestive heart failure, chronic ... organizations that have excellent programs for the delivery and improvement of disease management ...
(Date:3/23/2017)... CO (PRWEB) , ... March 23, 2017 , ... ... serving the families and businesses of the greater Fort Collins area, has unveiled ... in their ongoing community involvement program. Donations to this worthy cause may now ...
(Date:3/23/2017)... ... March 23, 2017 , ... ?This conference will prominently feature 150+ Hospital and Health System Executive ... Healthcare: Susan Salka , 43rd President of the United States of America: George ... Life In and Out of the Ring: Sugar Ray Leonard , JD, Chairperson, ...
Breaking Medicine News(10 mins):